Topiramate and metabolic acidosis: an evolving story

References

• LaRoche SM, Helmers SL. The new antiepileptic drugs: scientific review. JAMA. 2004;291(5):605–614.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Ben-Menachem E, Shank RP, et al. Topiramate monotherapy in epilepsy and migraine prevention. Clin Ther. 2005;27(2):154–165.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Di Fiore A, De Simone G, et al. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008;13(2):383–392.
   PubMed Web of Science ®Google Scholar
• Pigott K, Galizia I, Vasudev K, et al. Topiramate for acute affective episodes in bipolar disorder in adults. Cochrane Database Syst Rev. 2016;2016(9). DOI:10.1002/14651858.CD003384.pub3
   Web of Science ®Google Scholar
• Baltieri DA, Daró FR, Ribeiro PL, et al. Effects of topiramate or naltrexone on tobacco use among male alcohol-dependent outpatients. Drug Alcohol Depend. 2009;105(1–2):33–41.
   PubMed Web of Science ®Google Scholar
• Mula M, Cavanna AE, Monaco F. Psychopharmacology of topiramate: from epilepsy to bipolar disorder. Neuropsychiatr Dis Treat. 2006;2(4):475–488.
   PubMedGoogle Scholar
• Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia. 2000;41(Suppl 1):S35–S39.
   PubMed Web of Science ®Google Scholar
• Au JN, Waslo CS, McGwin G, et al. Acetazolamide-induced nephrolithiasis in idiopathic intracranial hyper tension patients. J Neuro-Ophthalmol. 2016;36(2):126–130.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Advisory committee meeting for phentermine/topiramate (Qnexa). Silver Spring, MD: Division of Metabolism and Endocrinology Products (DMEP) Office of Drug Evaluation II Center for Drug Evaluation and Research, US; 2010 Jul 15. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommitee/UCM218824.pdf
   Google Scholar
• Dell’Orto VG, Belotti EA, Goeggel-Simonetti B, et al. Metabolic disturbances and renal stone promotion on treatment with topiramate: A systematic review. Br J Clin Pharmacol. 2014;77(6):958–964.
   PubMed Web of Science ®Google Scholar
• Groeper K, McCann ME. Topiramate and metabolic acidosis: a case series and review of the literature. Paediatr Anaesth. 2005;15(2):167–170.
   PubMed Web of Science ®Google Scholar
• Takeoka M, Holmes GL, Thiele E, et al. Topiramate and metabolic acidosis in pediatric epilepsy. Epilepsia. 2001;42(3):387–392.
   PubMed Web of Science ®Google Scholar
• Philippi H, Boor R, Reitter B. Topiramate and metabolic acidosis in infants and toddlers. Epilepsia. 2002;43(7):744–747.
   PubMed Web of Science ®Google Scholar
• Ture H, Keskin O. The frequency and severity of metabolic acidosis related to topiramate. J Int Med Res. 2016;44(6):1376–1380.
   PubMed Web of Science ®Google Scholar
• Stowe CD, Bollinger T, James LP, et al. Acute mental status changes and hyperchloremic metabolic acidosis with long-term topiramate therapy. Pharmacotherapy. 2000;20(1):105–109.
   PubMed Web of Science ®Google Scholar
• Rodriguez L, Valero R, Febregas N. Intraoperative metabolic acidosis induced by chronic topiramate intake in neurosurgical patients. J Neurosurg Anesth. 2008;20:67–68.
   PubMed Web of Science ®Google Scholar
• Tartara A, Sartori I, Manni R, et al. Efficacy and safety of topiramate in refractory epilepsy: A long-term prospective trial. Ital J Neurol Sci. 1996;17(6). DOI:10.1007/BF01997718
   PubMedGoogle Scholar
• Wilner A, Raymond K, Pollard R. Topiramate and metabolic acidosis. Epilepsia. 1999;40(6):792–795.
   PubMed Web of Science ®Google Scholar
• Topamax package insert. [cited 2017 May 31]. Available from: https://www.accessdata.fda.gov
   Google Scholar
• Gutiérrez López C, Plascencia-Álvarez N, AguilarQuiñones S. Relación entre topiramato y nefrolitiasis en una muestra de pacientes mexicanos con epilepsia refractaria. Rev Mex Neuroci. 2008;9:438–444.
   Google Scholar
• Maalouf NM, Langston JP, Van Ness PC, et al. Nephrolithiasis in topiramate users. Urol Res. 2011;39(4):303–307.
   PubMedGoogle Scholar
• Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology. 2003;61(4):456–464. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12939417.
   PubMed Web of Science ®Google Scholar
• Mirza N, Marson AG, Pirmohamed M. Effect of topiramate on acid-base balance: extent, mechanism and effects. Br J Clin Pharmacol. 2009;68(5):655–661.
   PubMed Web of Science ®Google Scholar
• Winum J-Y, Poulsen S-A, Supuran CT. Therapeutic applications of glycosidic carbonic anhydrase inhibitors. Med Res Rev. 2009;29(3):419–435.
   PubMed Web of Science ®Google Scholar
• Maryanoff BE, McComsey DF, Costanzo MJ, et al. Comparison of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II by using topiramate as a structural platform. J Med Chem. 2005;48(6):1941–1947.
   PubMed Web of Science ®Google Scholar
• Shank RP, Gardocki JF, Vaught JL, et al. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia. 1994;35(2):450–460.
   PubMed Web of Science ®Google Scholar
• Welch BJ, Graybeal D, Moe OW, et al. Biochemical and stone-risk profiles with topiramate treatment. Am J Kidney Dis. 2006;48(4):555–563.
   PubMed Web of Science ®Google Scholar
• Krieger NS, Sessler NE, Bushinsky DA. Acidosis inhibits osteoblastic and stimulates osteoclastic activity in vitro. Am J Physiol. 1992;262(3 Pt 2):F442–448.
   PubMedGoogle Scholar
• Caldas A, Broyer M, Dechaux M, et al. Primary distal tubular acidosis in childhood: clinical study and long-term follow-up of 28 patients. J Pediatr. 1992;121(2):233–241.
   PubMed Web of Science ®Google Scholar
• Allan Jhagroo R, Wertheim ML, Penniston KL. Alkali replacement raises urinary citrate excretion in patients with topiramate-induced hypocitraturia. Br J Clin Pharmacol. 2016;81(1):131–136.
   PubMed Web of Science ®Google Scholar